

Samira Fafi-Kremer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9041956/publications.pdf>

Version: 2024-02-01

99
papers

12,116
citations

81900

39
h-index

38395

95
g-index

114
all docs

114
docs citations

114
times ranked

23813
citing authors

#	ARTICLE	IF	CITATIONS
1	High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. <i>Intensive Care Medicine</i> , 2020, 46, 1089-1098.	8.2	2,244
2	Neurologic Features in Severe SARS-CoV-2 Infection. <i>New England Journal of Medicine</i> , 2020, 382, 2268-2270.	27.0	2,092
3	Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. <i>Nature</i> , 2021, 596, 276-280.	27.8	1,803
4	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , 2021, 27, 917-924.	30.7	617
5	Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. <i>Blood</i> , 2006, 107, 3053-3057.	1.4	390
6	Brain MRI Findings in Severe COVID-19: A Retrospective Observational Study. <i>Radiology</i> , 2020, 297, E242-E251.	7.3	333
7	Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients. <i>Critical Care</i> , 2020, 24, 491.	5.8	251
8	Neurologic and neuroimaging findings in patients with COVID-19. <i>Neurology</i> , 2020, 95, e1868-e1882.	1.1	186
9	Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France. <i>Emerging Infectious Diseases</i> , 2021, 27, 113-121.	4.3	176
10	Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection. <i>EBioMedicine</i> , 2021, 71, 103561.	6.1	172
11	Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine. <i>Kidney International</i> , 2021, 99, 1498-1500.	5.2	163
12	Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. <i>Journal of Hepatology</i> , 2011, 54, 566-576.	3.7	161
13	Monoclonal Anti-Claudin 1 Antibodies Prevent Hepatitis C Virus Infection of Primary Human Hepatocytes. <i>Gastroenterology</i> , 2010, 139, 953-964.e4.	1.3	151
14	Coronavirus disease 2019 in pregnancy was associated with maternal morbidity and preterm birth. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 914.e1-914.e15.	1.3	147
15	Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 1487-1489.	5.2	126
16	Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. <i>Journal of Experimental Medicine</i> , 2010, 207, 2019-2031.	8.5	125
17	Long-Term Shedding of Infectious Epstein-Barr Virus after Infectious Mononucleosis. <i>Journal of Infectious Diseases</i> , 2005, 191, 985-989.	4.0	108
18	Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. <i>EBioMedicine</i> , 2020, 59, 102915.	6.1	101

#	ARTICLE	IF	CITATIONS
19	Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1762-e1765.	5.8	93
20	Development of hepatitis C virus vaccines: challenges and progress. <i>Expert Review of Vaccines</i> , 2009, 8, 333-345.	4.4	82
21	Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study. <i>Lancet Microbe</i> , The, 2021, 2, e60-e69.	7.3	78
22	SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2600-2607.	3.8	76
23	Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. <i>Journal of Hepatology</i> , 2012, 57, 17-23.	3.7	72
24	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. <i>Science Translational Medicine</i> , 2022, 14, eabj7521.	12.4	71
25	Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. <i>Blood</i> , 2010, 115, 1145-1155.	1.4	68
26	In-depth virological assessment of kidney transplant recipients with COVID-19. <i>American Journal of Transplantation</i> , 2020, 20, 3162-3172.	4.7	68
27	Assessment of automated DNA extraction coupled with real-time PCR for measuring Epstein-Barr virus load in whole blood, peripheral mononuclear cells and plasma. <i>Journal of Clinical Virology</i> , 2004, 30, 157-164.	3.1	67
28	Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies. <i>Gastroenterology</i> , 2012, 143, 223-233.e9.	1.3	66
29	Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of Infectious Diseases</i> , 2021, 224, 983-988.	4.0	65
30	Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 326-334.	6.1	64
31	First case of COVID-19 in a kidney transplant recipient treated with belatacept. <i>American Journal of Transplantation</i> , 2020, 20, 1944-1946.	4.7	55
32	Refining "Long-COVID" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1747-1763.	4.0	55
33	Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. <i>Science Translational Medicine</i> , 2022, 14, eabl6141.	12.4	52
34	A new hot spot for tick-borne encephalitis (TBE): A marked increase of TBE cases in France in 2016. <i>Ticks and Tick-borne Diseases</i> , 2018, 9, 120-125.	2.7	49
35	Cerebrospinal Fluid Features in Patients With Coronavirus Disease 2019 and Neurological Manifestations: Correlation with Brain Magnetic Resonance Imaging Findings in 58 Patients. <i>Journal of Infectious Diseases</i> , 2021, 223, 600-609.	4.0	47
36	Rapid and early virological response to chronic hepatitis C treatment with IFN α 2b or PEG-IFN α 2b plus ribavirin in HIV/HCV co-infected patients. <i>Gut</i> , 2007, 56, 1111-1116.	12.1	46

#	ARTICLE	IF	CITATIONS
37	A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. <i>Kidney International</i> , 2022, 101, 1073-1076.	5.2	44
38	Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. <i>Aids</i> , 2015, 29, 1665-1671.	2.2	43
39	HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-2012: impact on susceptibility to first-line strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2084-2089.	3.0	42
40	Torquetenovirus viremia for early prediction of graft rejection after kidney transplantation. <i>Journal of Infection</i> , 2019, 79, 56-60.	3.3	40
41	Neutralizing antibodies in hepatitis C virus infection. <i>World Journal of Gastroenterology</i> , 2007, 13, 4824.	3.3	40
42	Hepatitis C virus vaccines "Progress and perspectives. <i>Microbial Pathogenesis</i> , 2013, 58, 66-72.	2.9	34
43	Biomarkers of Cytokine Release Syndrome Predict Disease Severity and Mortality From COVID-19 in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, 158-169.	1.0	34
44	Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab. <i>Emerging Infectious Diseases</i> , 2018, 24, 1594-1596.	4.3	33
45	SARS-CoV-2 viral load in nasopharyngeal swabs in the emergency department does not predict COVID-19 severity and mortality. <i>Academic Emergency Medicine</i> , 2021, 28, 306-313.	1.8	33
46	Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 2871-2875.	4.7	33
47	Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients. <i>World Journal of Gastroenterology</i> , 2009, 15, 753.	3.3	33
48	Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1489-1499.	4.0	32
49	Early Evolution of Hepatitis C Virus (HCV) Quasispecies after Liver Transplant for HCV-Related Disease. <i>Journal of Infectious Diseases</i> , 2007, 196, 528-536.	4.0	30
50	Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. <i>Hepatology</i> , 2016, 63, 1120-1134.	7.3	30
51	Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115181.	1.8	29
52	Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3842-3852.	3.9	27
53	45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches. <i>Critical Reviews in Microbiology</i> , 2017, 43, 178-195.	6.1	27
54	Microcephaly Caused by Lymphocytic Choriomeningitis Virus. <i>Emerging Infectious Diseases</i> , 2017, 23, 1548-1550.	4.3	26

#	ARTICLE	IF	CITATIONS
55	Evaluation of the Epstein-Barr Virus R-Gene Quantification Kit in Whole Blood with Different Extraction Methods and PCR Platforms. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 78-84.	2.8	25
56	Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipientsâ€”Results from a proof-of-concept study. <i>American Journal of Transplantation</i> , 2021, 21, 329-337.	4.7	24
57	Neutralizing Antibodies and Pathogenesis of Hepatitis C Virus Infection. <i>Viruses</i> , 2012, 4, 2016-2030.	3.3	23
58	SARS-CoV-2 viral dynamics in immunocompromised patients. <i>American Journal of Transplantation</i> , 2021, 21, 1667-1669.	4.7	23
59	An unusually high substitution rate in transplant-associated BK polyomavirus in vivo is further concentrated in HLA-C-bound viral peptides. <i>PLoS Pathogens</i> , 2018, 14, e1007368.	4.7	22
60	Tick-Borne Encephalitis in Auvergne-RhÃ´ne-Alpes Region, France, 2017â€“2018. <i>Emerging Infectious Diseases</i> , 2019, 25, 1944-1948.	4.3	20
61	Intravenous Immunoglobulin Administration Significantly Increases BKPyV Genotype-Specific Neutralizing Antibody Titers in Kidney Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
62	Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 3808-3810.	4.7	20
63	Persistence of SARS-CoV-2 antibodies in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2307-2310.	4.7	20
64	D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 39.	2.4	20
65	Frequent Compartmentalization of Hepatitis C Virus with Leukocyte-Related Amino Acids in the Setting of Liver Transplantation. <i>Journal of Infectious Diseases</i> , 2008, 198, 1656-1666.	4.0	19
66	Tick-borne encephalitis virus: molecular determinants of neuropathogenesis of an emerging pathogen. <i>Critical Reviews in Microbiology</i> , 2019, 45, 472-493.	6.1	19
67	Real-time quantitative PCR for assessment of antiviral drug effects against Epstein-Barr virus replication and EBV late mRNA expression. <i>Journal of Virological Methods</i> , 2007, 143, 38-44.	2.1	18
68	Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 751-761.	3.0	18
69	Long-term storage and safe retrieval of human papillomavirus DNA using FTA elute cards. <i>Journal of Virological Methods</i> , 2016, 229, 60-65.	2.1	16
70	Clinical utility of leflunomide for BK polyomavirus associated nephropathy in kidney transplant recipients: A multicenter retrospective study. <i>Transplant Infectious Disease</i> , 2019, 21, e13058.	1.7	13
71	Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. <i>Viruses</i> , 2022, 14, 1491.	3.3	13
72	Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1429-1439.	0.6	13

#	ARTICLE	IF	CITATIONS
73	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naïve chronically HIV-infected patients in 2015/2016 in France. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1417-1424.	3.0	12
74	Toward Standardization of BK Virus Monitoring: Evaluation of the BK Virus R-gene Kit for Quantification of BK Viral Load in Urine, Whole-Blood, and Plasma Specimens. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4298-4304.	3.9	11
75	EBV limbic encephalitis after allogeneic hematopoietic stem cell transplantation. <i>Journal of Neuroradiology</i> , 2010, 37, 189-191.	1.1	10
76	Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds. <i>GeroScience</i> , 2022, 44, 1229-1240.	4.6	10
77	Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization. <i>Journal of Infectious Diseases</i> , 2013, 207, 1306-1315.	4.0	9
78	Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1045-1053.	3.0	9
79	Challenges for HCV vaccine development in HIV/HCV coinfection. <i>Expert Review of Vaccines</i> , 2012, 11, 791-804.	4.4	8
80	Antiretroviral-naïve and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 566-572.	3.0	8
81	Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 183-193.	3.0	8
82	Presence of active myocarditis at the 6-month follow-up appointment for a severe form of COVID-19: a case report. <i>ESC Heart Failure</i> , 2021, 8, 4307-4312.	3.1	8
83	Outbreak of SARS-CoV-2 infection in a long-term care facility after COVID-19 BNT162b2 mRNA vaccination. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1537-1539.	6.0	8
84	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.8	8
85	Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2351-2354.	3.0	7
86	Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia. <i>Journal of Clinical Virology</i> , 2022, 148, 105120.	3.1	7
87	Quantification of gp350/220 Epstein-Barr Virus (EBV) mRNA by Real-Time Reverse Transcription-PCR in EBV-Associated Diseases. <i>Clinical Chemistry</i> , 2004, 50, 1814-1817.	3.2	6
88	Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 1107.	2.5	5
89	Inadequate Immune Humoral Response against JC Virus in Progressive Multifocal Leukoencephalopathy Non-Survivors. <i>Viruses</i> , 2020, 12, 1380.	3.3	4
90	Clinical and Virological Follow-up of a Cohort of 76 COVID-19 Older Hospitalized Adults. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1167-1170.	2.6	4

#	ARTICLE	IF	CITATIONS
91	Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine. <i>Frontiers in Immunology</i> , 2022, 13, 790212.	4.8	3
92	Neuroimaging of Epstein-Barr virus infections in children. <i>Pediatric Radiology</i> , 2008, 38, 354-355.	2.0	1
93	Virus-host interactions during hepatitis C virus entry " implications for pathogenesis and novel treatment approaches. <i>Virologica Sinica</i> , 2008, 23, 124-131.	3.0	1
94	Letter to the Editor concerning "Cytomegalovirus prevention strategies and the risk of BK polyomavirus viremia and nephropathy". <i>American Journal of Transplantation</i> , 2019, 19, 3438-3439.	4.7	1
95	The Authors Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1578.2-1578.	6.1	0
96	Le BK virus en greffe r�onale. <i>Revue Francophone Des Laboratoires</i> , 2019, 2019, 44-52.	0.0	0
97	High severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion rate among geriatric staff from Strasbourg University Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.8	0
98	Proposition d'une nouvelle strat�gie pour �viter la r�infection du greffon par le virus de l'h�patite C apr�s transplantation h�patique. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2008, 192, 1657-1668.	0.0	0
99	COVID-19 exposure in SARS-CoV-2-seropositive hospital staff members during the first pandemic wave at Strasbourg University Hospital, France. <i>Infectious Diseases Now</i> , 2021, , .	1.6	0